Le Lézard
Classified in: Health, Science and technology
Subject: MISCELLANEOUS

Harvard Bioscience Names Michael Rossi Chief Financial Officer


HOLLISTON, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Michael Rossi has been named Chief Financial Officer, effective immediately.  Rossi most recently served as Chief Financial Officer of Laborie Medical Technologies, a global medical devices company.

Jim Green, Chairman, President and CEO stated, "Mike Rossi's deep experience in finance, public company accounting, global business operations, and restructuring make him the perfect leader to partner with me to rapidly improve Harvard Bioscience's financial and operating performance."

Rossi said, "I am honored to join Harvard Bioscience and work with Jim and the company's talented finance team to execute with urgency and quickly earn the trust of our shareholders."

Rossi, 45, brings to Harvard Bioscience more than 19 years of finance and operational expertise. Prior to serving as Chief Financial Officer of Laborie Medical Technologies, he served as Chief Financial Officer of Medical Specialties Distributors, a healthcare supply chain management solutions company for over three years. Prior to that role, Rossi held finance roles of increasing responsibility at various public companies, including Haemonetics Corporation, The Princeton Review, Inc., American Tower Corporation, Sonus Networks and Manufacturers' Services Limited. He began his professional career as an accountant at PricewaterhouseCoopers. Rossi earned a Bachelor of Science in accounting, cum laude, from Babson College and a Masters of Business Administration, cum laude, from Babson College's Olin School of Management.

About Harvard Bioscience

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.

Contact Information

David Sirois
Director, Corporate Accounting & SEC Reporting
508-893-8999

 


These press releases may also interest you

at 17:55
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....



News published on and distributed by: